Cladribine
NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic
March 3, 2021Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis
NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …
Merck Serono sets up cancer platform
July 3, 2013Research and Development, Sales and Marketing Cancer, Cladribine, Merck Serono, kgaa
Merck Serono is attempting to speed up R&D on products which stimulate the immune system to fight cancer by establishing …
Merck KGaA swings axe over Serono operations
April 25, 2012Manufacturing and Production, Research and Development, Sales and Marketing Cladribine, MS, Merck KGaA, Switzerland, job cuts
Merck KGaA will cut around 500 jobs from its pharmaceutical unit in Switzerland, the firm has announced. The company said …
Merck licences new MS drug
September 19, 2011Research and Development Cladribine, Merck KGaA, Merck Serono, PI-2301
Merck KGaA has in-licensed a new multiple sclerosis drug and aims to start it in phase II studies later this …
Merck scraps MS pill cladribine
June 23, 2011Research and Development, Sales and Marketing Cladribine, Merck KGaA, Movectro, multiple sclerosis
Merck KGaA has pulled all pending applications for its multiple sclerosis pill Movectro and will withdraw it from the markets …
FDA knocks back Merck KGaA’s oral MS drug
March 2, 2011Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs
US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …
Merck KGaA sales soar
February 21, 2011Sales and Marketing 2010 pharma results, Cladribine, Merck KGaA, Merck Serono, Movectro
Merck KGaA’s sales jumped last year by nearly a fifth as recent acquisitions and strong growth on core products set …
Merck Serono halts Movectro European licence application
February 18, 2011Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis
Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …
Novartis MS drug steals march over Merck rival
January 24, 2011Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis
Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …
Key drug launches for 2011
January 20, 2011Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir
This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …
Europe committee rejects MS treatment Movectro
September 24, 2010Sales and Marketing Cladribine, Merck Serono Movectro
The Europe Medicines Agency has rejected Merck Serono’s new multiple sclerosis treatment Movectro, saying its benefits do not outweigh its …
Gilenya approved as new frontline MS treatment
September 22, 2010Research and Development, Sales and Marketing Cladribine, FDA, Novartis, gilenya
Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …
Gilenya approved in Russia, awaits FDA decision
September 16, 2010Sales and Marketing Cladribine, Gilena, MS
Novartis has won approval for its MS drug Gilenya in Russia but still awaits the FDA’s decision on its fate …
Merck KGaA’s oral MS therapy gains US priority review
July 29, 2010Sales and Marketing Cladribine, MS, Merck KGaA
Merck’s cladribine has been granted a priority review status by the FDA in a move that could see it come …
First oral MS treatment approved in Russia
July 12, 2010Sales and Marketing Cladribine, MS, Merck Serono, Movectro
Regulators in Russia have approved Merck Serono’s cladribine, lining up the drug to be the first oral treatment for multiple …
